Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer’s disease: the role of the ApoE genotype

Selezneva N.D.; Gavrilova S.I.; Kolykhalov I.V.

doi:https://doi.org/10.17116/jnevro202012010231

Selezneva N.D.

Mental Health Research Centre

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Kolykhalov I.V.

Mental Health Research Center

ORCID: 0000-0002-2358-1579

Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer’s disease: the role of the ApoE genotype

Authors:

Selezneva N.D., Gavrilova S.I., Kolykhalov I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2): 31‑38

DOI: 10.17116/jnevro202012010231

Read: 3428 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Selezneva ND, Gavrilova SI, Kolykhalov IV. Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer’s disease: the role of the ApoE genotype. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2):31‑38. (In Russ.)
https://doi.org/10.17116/jnevro202012010231

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess the delayed effect of course therapy with cerebrolysin on the cognitive functioning of the first degree relatives of patients with Alzheimer’s disease (AD), including, depending on the ApoE4 genotype.

MATERIAL AND METHODS

A cohort of 72 blood relatives of patients with AD, including 46 with objectively confirmed clinical and neuropsychological examination signs of mild cognitive dysfunction (group 1) and 26 (group 2) with cognitive impairment that meets the diagnostic criteria of mild cognitive impairment (ICD-10 F06.7), was studied. The dynamics of the initial (0 day) indicators of cognitive functioning was compared immediately after a four-week course of treatment with cerebrolysin infusions, as well as 1 and 2 months after its completion, depending on the presence of ApoE4(+) or ApoE4(–) genotype. Clinical, psychopathological, psychometric, follow-up, molecular-genetic and statistical methods were used.

RESULTS

A positive prolonged effect of course therapy with cerebrolysin on cognitive functioning of the first degree relatives of patients with AD was established in both groups. A significant negative effect of the ApoE4(+) genotype on the immediate and delayed effects of cerebrolysin treatment has been proven.

CONCLUSION

The results can form the basis for the development of therapeutic measures aimed at preventing the progression of cognitive impairment and the development of dementia in the first degree relatives of patients with AD as those with the highest risk of dementia.

Keywords:

Alzheimer’s disease

cognitive impairment

MCI

cerebrolysin

Authors:

Selezneva N.D.

Mental Health Research Centre

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Kolykhalov I.V.

Mental Health Research Center

ORCID: 0000-0002-2358-1579

Received:

19.06.2020

Accepted:

08.07.2020

Close metadata

References:

Chikina ES, Mednikov OI, Belousov YuB. Pharmacoeconomic aspects of treatment of dementia in the Russian Federation. Medical Journal of the Russian Federation. 2005;13(20):1354-1360.
Prince M, Wimo AGM, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015.
La Rue A, O’Hara R, Matsuyama SS, Jarvik LF. Cognitive changes in young-old adults: effect of family history of dementia. J Clin Exp Neuropsychol. 1995;17:60-70. https://doi.org/10.1080/13803399508406582
Jarvik LF, Brazer D. Children of Alzheimer parents: An Overview. J Geriatr Psychiatry Neurol. 2005;18:181-186. https://doi.org/10.1177/0891988705281859
Gary W Small, Anna Okonek, Mark A Mandelkern, Asenath La Rue. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriatr. 1994;6:23-44. https://doi.org/10.1017/s1041610294001596
Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62:1990-1995.
Levy JA, Bergeson J, Putnam K, Rosen V. Context-specific memory and apolipoprotein E (APOE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer’s disease. J Int Neuropsychol Soc. 2004;10:362-370. https://doi.org/10.1017/s1355617704103044
Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol. 2005;18 (4):245-249. https://doi.org/10.1177/0891988705281882
Selezneva ND, Roshchina IF, Gavrilova SI, Fedorova YaB, Gantman MV, Korovaytseva GI, Kunizheva SS, Rogayev EI. Mental disturbances of a cognitive and not cognitive range at relatives of 1 degree of relationship of patients with Alzheimer’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(10):8-13.
Selezneva ND, Gavrilova SI, Roshchina IF, Korovaytseva GI. ApoE genotipe and mental disturbances of a cognitive and not cognitive range at relatives of the 1st degree of relationship of patients with Alzheimer’s disease. Psychiatry. 2013;1(57):13-23.
Selezneva ND, Roshchina IF. Comprehensive followup clinical and psychological study of cognitive features of mental activity in relatives of the first degree of relationship of patients with Alzheimer’s disease. Psychiatry. 2017;76(04):27-36.
Breithner JCS. Clinical genetics and genetic counselling in Alzheimer’s disease. Annals of Internal Medicine. 1991;115:601-606. https://doi.org/10.7326/0003-4819-601
McGuffin P, Michael J Owen, Michael C O’Donovan, Thapar A, Irving I Gottesman Gl. Seminars in Psychiatric Genetics. London: Gaskell; 1994. https://doi.org/10.1136/bmj.309.6957.818a
Gavrilova SI, Fedorova YaB, Kolyhalov IV, Odinak MM, Emelin AYu, Kashin AV, Selezneva ND, Kalyn YaB, Roshchina IF. The therapeutic potential of cerebrolysin in the preventive treatment of Alzheimer’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2008;108(8):24-29.
Serge Gauthier JV, Proano, Jiamping Jia, Lutz Froelich, Johannes Vester, Edith Doppler. Cerebrolysin in Mild-to-Moderate Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39:340-355. https://doi.org/10.1016/j.jalz.2014.05.1709
Gavrilova SI, Kolyhalov IV, Fyodorova YaB, Selezneva ND, Kalyn YaB, Roshchina IF, Odinak MM, Emelin AYu, Kashin AV, Gustov AV, Antipenko EA, Korshunova YuA, Davydova TA, Messler G. Possibilities of preventive therapy for Alzheimer’s disease: the results of a 3-year prospective open comparative study of the efficacy and safety of course therapy with cerebrolysin and cavinton in elderly patients with mild cognitive decline syndrome. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2010;110(1):62-69.
Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108:459-473. https://doi.org/10.1007/s007020170067
Zhang L, Chopp M, Meier DH, Winter S, Wang L, Szalad A, Lu M, Wei M, Cui Y, Zhang ZG. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:1965-1972. https://doi.org/10.1161/strokeaha.111.000831
Yanlu Zhang, Michael Chopp, Yuling Meng, Zheng Gang Zhang, Edith Doppler, Asim Mahmood, Ye Xiong. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. Journal of Neurosugery. 2013;118:1343-1355. https://doi.org/10.3171/2013.3.jns122061
Selezneva ND, Roshchina IF, Korovaytseva GI, Gavrilova SI. Prevention of progression of cognitive deficiency in relatives (1st degree of kinship) of patients with Alzheimer’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;10:30-36. https://doi.org/10.17116/jnevro201811810130
Korovajceva GI, Shcherbatyh TV, Selezneva ND, Gavrilova SI, Golimbet VE, Voskresenskaya NI, Rogaev EI. Genetic association between alleles of the apolipoprotein E gene (APOE) and various forms of Alzheimer’s disease. Genetika. 2001;37(4):529-535.